Tuvonralimab

Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2].

Product Specifications

CAS Number

[2417649-44-4]

Product Name Alternative

PSB-205; QL1706 (iparomlimab/tuvonralimab) ; PBS105

UNSPSC

12352203

Target

CTLA-4

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tuvonralimab.html

Purity

99.14

Solubility

10 mM in DMSO

Smiles

[Tuvonralimab]

Molecular Weight

(145 kDa)

References & Citations

[1]Keam SJ. Iparomlimab and Tuvonralimab: First Approval. Drugs. 2025 May;85 (5) :699-706.|[2]Ian Wilkinson, et al. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022 Jan-Dec;14 (1) :2123299.